Molecule News and Research

RSS

New stem cell-infused patch improves heart function after myocardial infarction

University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

16 Nov 2010

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

Science and precedent do not support biosimilar approach for plasma protein therapies

The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.

15 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

Researchers suspect amyloid beta causes neural damage in Alzheimer's disease

Researchers suspect that a protein superstructure called amyloid beta is responsible for much of the neural damage of Alzheimer's disease. A new study at the University of California, San Diego, shows that amyloid beta disrupts one of the brain's anti-oxidant proteins and demonstrates a way to protect that protein, and perhaps others, from amyloid's harmful effects.

11 Nov 2010

Portugal research groups awarded Gates Foundation grants

Two research groups in Portugal are to receive Grand Challenges Exploration Grants from the Bill & Melinda Gates Foundation. One of these research teams is led by Miguel Prud-ncio, at the Instituto de Medicina Molecular (IMM), and the other by Miguel Soares, at the Instituto Gulbenkian de Ci-ncia (IGC) together with Henrique Silveira, at the Instituto de Higiene e Medicina Tropical (IHMT).

11 Nov 2010

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

11 Nov 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

11 Nov 2010

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Newly published research by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sheds light on a poorly understood, acute illness called Immune Reconstitution Inflammatory Syndrome (IRIS) that develops in some HIV-infected individuals soon after they begin antiretroviral therapy.

11 Nov 2010

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

Adolor receives U.S. Patent for beloxepin to treat pain

Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.

11 Nov 2010

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

SuperGen discontinues clinical development of SGI-1776 PIM kinase drug candidate

SuperGen, Inc. today announced that it has discontinued clinical development of its phase 1 PIM kinase drug candidate, SGI-1776, while continuing development of the PIM inhibitor program.

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

Researchers identify molecular cascade that drives process of reconnection in adult brain after stroke

10 Nov 2010

Molecule News and Research

New stem cell-infused patch improves heart function after myocardial infarction

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Science and precedent do not support biosimilar approach for plasma protein therapies

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Novel mechanism regulating circadian rhythm identified

Researchers suspect amyloid beta causes neural damage in Alzheimer's disease

Portugal research groups awarded Gates Foundation grants

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Adolor receives U.S. Patent for beloxepin to treat pain

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

SuperGen discontinues clinical development of SGI-1776 PIM kinase drug candidate

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

Researchers identify molecular cascade that drives process of reconnection in adult brain after stroke

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News